Clinical Trials on Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line in Finland
Total 5 results
-
TILT Biotherapeutics Ltd.Merck Sharp & Dohme LLCRecruitingPlatinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditionsUnited States, Finland
-
AstraZenecaMerck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.Active, not recruitingAdvanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum ChemotherapyKorea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
-
UMC UtrechtTurku University Hospital; University of Bologna; University of Roma La Sapienza and other collaboratorsRecruitingQuality of Life | Pain | Neoplasm Metastasis | Bone Cancer | Bone Metastases | Tumor | Bone Neoplasm | Bone Lesion | Cancer Induced Bone PainNetherlands, Germany, Finland, Italy
-
Women and Infants Hospital of Rhode IslandTerminatedBreast Cancer | Ovarian CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)UnknownFatigue | Anxiety | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC... and other conditionsUnited States